InsiderClue
← All stocks

Janux Therapeutics, Inc.

JANX Net selling
CIK 0001817713 #2496 in the set updated 19 Sep 2026
Bought (120 mo)
$207.28M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$365.17M
$6.73M on a plan · $19.32M straight out of an exercise
Sold at will
$339.13M
60 of 103 sales
Net
−$157.90M
−$131.85M against sales at will

By person

24 insiders · 125 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Avalon Ventures XI, L.P. entity
10% owner
$15.69M (2)
$205.38M (47)
−$189.69M
8,666,664
14.18%
$121.58M
+102.9%
RA CAPITAL MANAGEMENT, L.P. entity
Director
$135.21M (8)
—
+$135.21M
1,060,156
1.73%
$14.87M
—
Lichter Jay
10% owner
$15.69M (2)
$82.30M (4)
−$66.61M
7,826,510
12.80%
$109.80M
—
Reardon Tighe
Acting Chief Financial Officer
$15.69M (2)
$45.04M (2)
−$29.36M
7,992,445
13.07%
$112.13M
+129.3%
Campbell David Alan
President and CEO
—
$6.61M (11) scheduled
−$6.61M
264,742
0.4330%
$3.71M
−20.3%
Meyer Andrew Hollman
Chief Business Officer
—
$4.22M (19) scheduled
−$4.22M
83,095
0.1359%
$1.17M
+18.0%
ORBIMED ADVISORS LLC entity
Director
$12.00M (2)
$10.59M (6)
+$1.41M
513,496
0.8399%
$7.20M
—
Thompson Peter A.
Director
$12.00M (2)
$10.59M (6)
+$1.41M
513,496
0.8399%
$7.20M
—
Bregua Corp entity
10% owner
$999.99K (1)
—
+$999.99K
3,749,250
6.13%
$52.60M
—
DiRaimondo Thomas
Chief Scientific Officer
—
$266.11K (3) scheduled
−$266.11K
155,825
0.2549%
$2.19M
+44.4%
Doyle Janeen Noel
Chief Corp. & Bus. Dev. Ofcr
—
$56.94K (1)
−$56.94K
75,941
0.1242%
$1.07M
—
Dobek Maria
Vice President, Accounting
—
$48.95K (2)
−$48.95K
32,270
0.0528%
$452.72K
+1,038%
McIver Zachariah
Chief Medical Officer
—
$37.26K (1)
−$37.26K
52,286
0.0855%
$733.52K
—
Winter Charles M.
Chief Technical Officer
—
$32.97K (1)
−$32.97K
106,321
0.1739%
$1.49M
+86.1%
Gujrathi Sheila
Director
—
—
—
118,889
0.1945%
$1.67M
+13.2%
CAPPS VICKIE L
Director
—
—
—
79,598
0.1302%
$1.12M
+24.3%
Go William
Chief Medical Officer
—
—
—
44,000
0.0720%
$617.28K
—
Robinson Byron
Chief Strategy Officer
—
—
—
28,000
0.0458%
$392.81K
—
DOBMEIER ERIC
Director
—
—
—
15,481
0.0253%
$217.18K
—
Hernday Natasha
Director
—
—
—
15,481
0.0253%
$217.18K
—
Simson Jake
Director
—
—
—
11,750
0.0192%
$164.84K
—
Kung Winston
Director
—
—
—
11,750
0.0192%
$164.84K
—
Barrett Ronald W
Director
—
—
—
11,750
0.0192%
$164.84K
—
McNulty Alana B.
Director
—
—
—
6,250
0.0102%
$87.68K
—

Individual transactions

12
Insider
Date
Role
Action
Shares
Price
Amount
Campbell David Alan
7 Jan 2025
President and CEO
Sold on a plan
5,000
$60.00
$300.00K
Campbell David Alan
24 Dec 2024
President and CEO
Sold on a plan
25,000
$56.19
$1.40M
Campbell David Alan
3 Dec 2024
President and CEO
Sold on a plan
15,000
$67.00
$1.01M
Campbell David Alan
25 Nov 2024
President and CEO
Sold on a plan
6,719
$52.04
$349.65K
Campbell David Alan
25 Nov 2024
President and CEO
Sold on a plan
18,281
$51.43
$940.23K
Campbell David Alan
28 Oct 2024
President and CEO
Sold on a plan
11,103
$53.94
$598.91K
Campbell David Alan
28 Oct 2024
President and CEO
Sold on a plan
13,897
$53.22
$739.65K
Campbell David Alan
27 Sep 2024
President and CEO
Sold on a plan
795
$47.84
$38.03K
Campbell David Alan
27 Sep 2024
President and CEO
Sold on a plan
5,248
$46.86
$245.90K
Campbell David Alan
27 Sep 2024
President and CEO
Sold on a plan
18,957
$46.09
$873.71K
DiRaimondo Thomas
27 Sep 2024
Chief Scientific Officer
Sold on a plan
675
$47.22
$31.88K
DiRaimondo Thomas
27 Sep 2024
Chief Scientific Officer
Sold on a plan
4,325
$46.21
$199.84K
Show all 125 transactions →

What was left out

Form 4 filings counted 136
Amendments (4/A) skipped 2
Filings about a different issuer 0
Unreadable filings 0
Joint filings 22
Sales on a Rule 10b5-1 plan 12
Sales straight out of an exercise 31
Sales at will 60
Transactions with no price 0
Shares from compensation/vesting 36,004,274
Sales filed before the plan box existed 12
History held since 14 Jun 2021